• NEWS
  • NEWS
  • NEWS
  • NEWS
  • NEWS
  • NEWS

The latest news on XGEN and its companies.

Linkedin

Follow us on LinkedIn

  • Portfolio Company News - Press Release

EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy

  • EPILEPSY GTx
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

iOnctura strengthens leadership with appointments of Chief Business Officer and Board Chair

  • iOnctura
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

iOnctura commences randomized Phase II study in metastatic uveal melanoma

  • iOnctura
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

iOnctura commences randomized Phase I/II study in non-small cell lung cancer

  • iOnctura
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

iOnctura bolsters leadership team with new appointments

  • iOnctura
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments

  • iOnctura
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new nonclinical data at ASH

  • iOnctura
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

Genespire announces that GENE202 has been granted Orphan Drug Designation by the FDA and EC for the treatment of methylmalonic acidemia

  • Genespire
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts

  • Protembis
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....